TableS6 from ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Supplementary Table 6 shows the summary of GLP toxicology study results
Fields of Study & Subjects
Monoclonal and Polyclonal Antibodies Research
Cancer Immunotherapy and Biomarkers
Toxin Mechanisms and Immunotoxins
Publication details
- Publication date
- 16 March 2026
- Language
- EN